Seattle, Sept. 09, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global human tuberculosis vaccine market is estimated to be valued at US$ 50.57 million in 2022 and is expected to exhibit a CAGR of 4.0% during the forecast period (2022-2030).
Key Trends and Analysis of the Global Human Tuberculosis Vaccine Market:
Increasing inorganic activities such as partnership among market players is expected to drive global human tuberculosis vaccine market growth over the forecast period. For instance, on March 16, 2022, Bharat Biotech, a global company in vaccine innovation and a developer of vaccines for infectious diseases, announced a partnership with Biofabri, a biopharmaceutical company, to develop, manufacture, and market a new tuberculosis vaccine in more than 70 countries in Southeast Asia and sub-Saharan Africa
Request Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/5209
Key Market Takeaways:
Increasing government initiatives such as campaigns to raise awareness regarding tuberculosis are anticipated to boost market growth over the forecast period. For instance, on March 22, 2022, the Centers for Disease Control and Prevention, a national public health agency of U.S., announced the launch of Think. Test. Treat TB, the first national communications campaign to increase testing and treatment for latent tuberculosis (TB) infection in the U.S.
Competitive Landscape:
Key players operating in the global human tuberculosis vaccine market include GlaxoSmithKline Plc, Merck & Co., Inc., Serum Institute of India Pvt. Ltd., Valneva SE, Archivel Farma, BIOFABRI (Zendal), Japan BCG Laboratory, GreenSignal Bio Pharma Private Limited (GSBPL), AJ Vaccines A/S, Taj Pharma India Limited and Biomed Lublin S.A.
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/5209
Market Segmentation:
- Global Human Tuberculosis Vaccine Market, by Route of Administration :
- Intradermal
- Percutaneous
- Global Human Tuberculosis Vaccine Market, by Age Group :
- Pediatrics
- Adults
- Global Human Tuberculosis Vaccine Market, by Distribution Channel :
- Public
- Private
- Global Human Tuberculosis Vaccine Market, By Region:
- North America
- By Country:
- U.S.
- Canada
- By Country:
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country:
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Country:
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Country:
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Country:
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Country/Region:
- North America
Related Market Intelligence Reports:
Antiparasitic Drugs Market, by Product Type (Anthelmintics (Anticestodal Drugs, Antitrematodal Drugs, Antinematodal Drugs), Antiprotozoal Agents (Antimalarials Agents, Antibabesial Agents, Antiamoebic Agents, Others), Ectoparasiticide (Antiscabietic Agents, Pediculicides)), by Route of Administration (Oral, Injectable, Topical), by Application (Human Health, Animal Health, Crop Health), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030
Prebiotics for Dietary Supplements Market, by Ingredient Type (Galacto-oligosaccharides (GOS), Fructo-oligosaccharides (FOS), Xylooligosaccharides (XOS), Isomaltooligosaccharides (IMO) and Human milk oligosaccharides (HMO)), by Source (Plant (Including Botanicals) and Animal), by Distribution Channel (B2B (Generic) (Broker and Direct (supplier to client)), B2C (Branded) (Pharmacies, Specialty Stores, and Hypermarket and supermarket)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
